title: Retinoid signaling is attenuated by proteasome-mediated degradation of retinoid receptors in human keratinocyte HaCaT cells.
abstract: The biological actions of retinoids are mediated by nuclear retinoid receptors, RAR and RXR, which are ligand-activated transcription factors. We investigated the mechanism of attenuation of retinoid receptor activity in human keratinocyte HaCaT cells. Treatment of HaCaT cells with all-trans-retinoic acid or 9-cis-retinoic acid reduced RARgamma and RXRalpha protein levels by one-half within 24 h. In contrast, retinoid treatment did not alter RARgamma or RXRalpha mRNA levels, suggesting that retinoids stimulate breakdown of their receptors. Pulse-chase studies revealed that retinoid treatment of HaCaT cells reduced RARgamma and RXRalpha half-lives by 50%, indicating that retinoids accelerate breakdown of their receptors. The proteasome inhibitor MG132 prevented retinoid-induced receptor loss. Furthermore, MG132 potentiated retinoid-induced receptor activity, as assessed by expression of the retinoid-regulated CRABP-II gene in HaCaT cells. These data demonstrate that retinoids attenuate retinoid receptor function by enhancing proteasome-mediated retinoid receptor breakdown in HaCaT cells. Proteasome-mediated degradation of RARgamma or RXRalpha in vitro was significantly reduced by the corepressor SMRT, which binds unliganded retinoid receptors. This protection from degradation was markedly diminished by ligand, which causes SMRT to dissociate from receptors. Ligand failed to relieve protection from degradation by SMRT of a mutant form of RXRalpha that binds SMRT in the presence and absence of ligand. Addition of coactivators TIF1, TIF2, and RIP140 had no effect on degradation of RARgamma or RXRalpha. In summary, ligand binding to retinoid receptors promotes proteasome-mediated receptor degradation via dissociation of SMRT. Ligand-stimulated receptor degradation results in attenuation of retinoid signaling.
authors.affiliation: Department of Dermatology, University of Michigan, Ann Arbor, Michigan 48109, USA.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Boudjelal
authors.forename: John J
authors.initials: JJ
authors.lastname: Voorhees
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Fisher
mesh_terms: D000328:Adult; D002460:Cell Line; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D015603:Keratinocytes / Q000201:enzymology / Q000502:physiology*; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex; D018168:Receptors, Retinoic Acid / Q000187:drug effects / Q000378:metabolism*; D047488:Retinoid X Receptors; D015398:Signal Transduction / Q000502:physiology; D012867:Skin / Q000166:cytology; D014157:Transcription Factors / Q000187:drug effects / Q000378:metabolism*; D014212:Tretinoin / Q000494:pharmacology / Q000502:physiology*; D000097768:Retinoic Acid Receptor gamma
chemical_list: D003546:Cysteine Endopeptidases; D004791:Enzyme Inhibitors; D009097:Multienzyme Complexes; D046988:Proteasome Endopeptidase Complex; D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; D014157:Transcription Factors; D014212:Tretinoin; D000097768:Retinoic Acid Receptor gamma